Matrix Metalloproteinases in Myasthenia Gravis
| Autor: | Gordon T. Plant, Geir Helgeland, Steven P. Luckman, Axel Petzold, Nils Erik Gilhus, Fredrik Romi |
|---|---|
| Přispěvatelé: | Neurology, NCA - Multiple Sclerosis and Other Neuroinflammatory Diseases |
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Systemic disease MMP3 Ocular myasthenia Enzyme-Linked Immunosorbent Assay medicine.disease_cause Autoantigens Neuromuscular junction Autoimmunity Pathogenesis Internal medicine Myasthenia Gravis medicine Humans Receptors Cholinergic Autoantibodies Autoimmune disease business.industry Middle Aged medicine.disease Myasthenia gravis body regions Endocrinology medicine.anatomical_structure Matrix Metalloproteinase 9 Neurology Immunology Matrix Metalloproteinase 2 Female Matrix Metalloproteinase 3 Neurology (clinical) business |
| Zdroj: | European Neurology, 65(1), 53-58. S. Karger AG Helgeland, G, Petzold, A F S, Luckman, S P, Gilhus, N E, Plant, G T & Romi, F R 2011, ' Matrix Metalloproteinases in Myasthenia Gravis ', European Neurology, vol. 65, no. 1, pp. 53-58 . https://doi.org/10.1159/000322737 |
| ISSN: | 0014-3022 |
| DOI: | 10.1159/000322737 |
| Popis: | Introduction: Myasthenia gravis (MG) is an autoimmune disease with weakness in striated musculature due to anti-acetylcholine receptor (AChR) antibodies or muscle specific kinase at the neuromuscular junction. A subgroup of patients has periocular symptoms only; ocular MG (OMG). Matrix metalloproteinases (MMP) are increased in several autoimmune diseases, including generalized MG (GMG), and have been suggested to play a role in immune cell infiltration, basement membrane breakdown and autoimmune pathogenesis. Methods: Total levels of MMP2, MMP3 and MMP9 were measured in serum by ELISA. Results: The MG patients had increased serum levels of MMP2 (median values 200.7 vs. 159.7 ng/ml, p < 0.001) and MMP9 (median values 629.6 vs. 386.4 ng/ml, p < 0.001) compared to controls. A subgroup of patients had increased MMP3 concentration (p = 0.001). The differences were not dependent on presence of AChR antibodies. No difference was observed between GMG and OMG patients with regard to MMP2 (p = 0.598), MMP3 (p = 0.450) and MMP9 (p = 0.271). Discussion: The increased MMP levels in our MG patients group and the lack of dependence on anti-AChR antibodies suggest that MMP2, MMP3 and MMP9 play a role in the development of MG. The similarities between GMG and OMG support OMG as a systemic disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|